Radiaction Medical has appointed Christopher Barys to serve as the company's U.S. president and chief commercial officer.
Barys will lead commercialization efforts and operations in the U.S. The Israel-based company develops medical devices that aim to provide radiation protection to medical staff during interventional procedures.
Barys joined Radiaction’s board of directors in 2023 and will remain on the board as he steps into his new role. Earlier this year, Radiaction raised $12.6 million in Series C2 funding led by U.S. private equity fund InnovaHealth Partners with participation from additional co-investors. The company is focused on expanding its U.S. presence, including adding new sites to its user base and growing its clinical publication pipeline.
Barys will join the Radiaction team at the Transcatheter Cardiovascular Therapeutics conference in San Francisco, to be held October 23 to 26.